Potentiation of ryanodine receptor-mediated calcium release by MAPK is responsible for epidermal transformation and

Pengcheng Wang1,2, Kristan H Cleveland1, Ayaz Shahid1

  • 1Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.

Insights

Epidermal growth factor (EGF) promotes skin cancer by activating MAPK/ERK and ryanodine receptors (RyRs), leading to calcium release. The drug carvedilol inhibits this process by targeting RyRs, offering a potential therapeutic strategy.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Pharmacology

Background:

  • Epidermal growth factor (EGF) promotes skin cell growth and transformation via the MAPK/ERK pathway.
  • The beta-blocker carvedilol inhibits EGF-induced skin cell transformation, but its mechanism is unclear.
  • Ryanodine receptors (RyRs) are implicated in calcium signaling and cellular processes.

Purpose of the Study:

  • To investigate the role of RyRs in EGF-promoted skin cell transformation.
  • To determine if carvedilol inhibits transformation by targeting RyRs.
  • To elucidate the interplay between MAPK/ERK, RyRs, and calcium release in carcinogenesis.

Main Methods:

  • Utilized JB6 mouse epidermal cells and a RyR2-tdTomato reporter mouse model.
  • Assessed EGF-induced ERK phosphorylation and RyR2 expression.
  • Measured 4-chloro-m-cresol (4-CMC)-evoked calcium release and JB6 cell transformation.
  • Employed RyR stabilizers, shRNAs, carvedilol derivatives, and in vivo UV radiation models.

Main Results:

  • EGF upregulated RyR2 and enhanced calcium release, which was inhibited by RyR stabilizers and MAPK/PLC inhibitors.
  • RyR agonists promoted JB6 transformation, while RyR stabilizers and calcium chelators blocked it.
  • Carvedilol's inhibitory effect on transformation was abolished by RyR shRNAs, and its derivatives' efficacy correlated with RyR inhibition.
  • In vivo, UV-induced skin damage was exacerbated by RyR activation and attenuated in RyR2-reduced mice.

Conclusions:

  • MAPK-mediated potentiation of RyR-induced calcium release is a critical pathway in skin carcinogenesis.
  • Carvedilol inhibits EGF-promoted skin cell transformation by targeting RyRs, independent of its beta-blocking activity.
  • Targeting RyR-mediated calcium signaling presents a potential therapeutic strategy for skin cancer prevention and treatment.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
6.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.2K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K